Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture

Key Points Analysts remain bullish about Alnylam despite its steep sell-off. The competitive landscape for Alnylam is more promising now thanks to two recent developments. Alnylam's valuation makes its risk-reward proposition look appealing. 10 stocks we like better than Alnylam Pharmaceuticals › There's no way to spin Alnylam Pharmaceuticals ' (NASDAQ: ALNY) stock performance in 2026 in a positive light. It's been downright ugly. Alnylam's share price plunged more than 50% year-to-date earlier this summer and remains around 40% below its peak. You might think that most Wall Street analysts would have thrown in the towel on Alnylam. However, that isn't the case at all. Instead, analysts remain overwhelmingly bullish about the biotech stock .